Journal of Endocrinological Investigation

, Volume 28, Issue 5, pp 285–293 | Cite as

Seladin-1 as a target of estrogen receptor activation in the brain: A new gene for a rather old story?

Review Article

Abstract

Experimental evidence indicates that estrogen exerts neuroprotective effects. According to the fact that Alzheimer’s disease (AD) is more common in post-menopausal women, estrogen treatment has been proposed. However, the beneficial effect of estrogen or selective estrogen receptor modulators (SERMs) in preventing or treating AD is a controversial issue, which will be summarized in this review. Recently, a novel gene, named selective AD indicator-1 (seladin-1), has been isolated and found to be down-regulated in brain regions affected by AD. Seladin-1, which is considered the human homolog of the plant protein DIMINUTO/DWARF1, confers protection against β-amyloid-mediated toxicity and from oxidative stress and is an effective inhibitor of caspase 3 activity, a key mediator of apoptosis. This review will present the up-to-date findings regarding seladin-1 and DIMINUTO/DWARF1. In addition, the possibility that seladin-1 may be a downstream effector of estrogen receptor activation in the brain, based on our recent experimental findings using a human fetal neuronal model, will be addressed.

Keywords

Seladin-1 DHCR24 estrogen selective estrogen receptor modulators Alzheimer’s disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wise PM. Estrogens and neuroprotection. Trends Endocrinol Metab 2002, 13: 229–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Behl C. 2003 Estrogen can protect neurons: modes of action. J Steroid Biochem Mol Biol 2002, 83: 195–7.CrossRefGoogle Scholar
  3. 3.
    Maggi A, Ciana P, Belcredito S, Vegeto E. Estrogens in the nervous system: mechanisms and nonreproductive functions. Ann Rev Physiol 2004, 66: 291–313.CrossRefGoogle Scholar
  4. 4.
    Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 2001, 81: 741–76.PubMedGoogle Scholar
  5. 5.
    Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer’s disease in women. Am J Epidemiol 1994, 140: 256–61.PubMedGoogle Scholar
  6. 6.
    Fillit HM. The role of hormone replacement therapy in the prevention of Alzheimer’s disease. Arch Intern Med 2002, 162: 1934–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience 2000, 101: 485–512.PubMedCrossRefGoogle Scholar
  8. 8.
    MacLusky NJ. Estrogen and Alzheimer’s disease: the apolipoprotein connection. Endocrinology 2004, 145: 3062–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Brinton RD. Impact of estrogen therapy on Alzheimer’s disease: a fork in the road? CNS Drugs 2004, 18: 405–22.PubMedCrossRefGoogle Scholar
  10. 10.
    Zandi PP, Carlson MC, Plassman BL et al. Hormone replacement therapy and incidence of Alzheimer disease in older women. JAMA 2002, 288: 2123–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease. JAMA 2002, 288: 2170–2.PubMedCrossRefGoogle Scholar
  12. 12.
    Dubal DB, Zhu H, Yu J et al. Estrogen receptor alpha, not beta, is a critical link in esradiol-mediated protection against brain injuery. Proc Natl Acad Sci USA 2001, 98: 1952–7.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Hu XY, Qin S, Lu YP, Ravid R, Swaab DF, Zhou JN. Decreased estrogen receptor-α expression in hippocampal neurons in relation to hyperphosphorylated tau in Alzheimer patients. Acta Neuropathol 2003, 106: 213–20.PubMedCrossRefGoogle Scholar
  14. 14.
    Wang L, Andersson S, Warner M, Gustafsson JA. Morphological abnormalities in the brains of estrogen receptor beta knockout mice. Proc Natl Acad Sci USA 2001, 98: 2792–6.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Hawkins MB, Thornton JW, Crews D, Skipper JK, Dotte A, Thomas P. Identification of a third distinct estrogen receptor and reclassification of estrogen receptors in teleosts. Proc Natl Acad Sci USA 2000, 97: 10751–6.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Toran-Allerand CD. Minireview: a plethora of estrogen receptors in the brain: where will it end? Endocrinology 2004, 145: 1069–74.PubMedCrossRefGoogle Scholar
  17. 17.
    Dhandapani KM, Brann DW. Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod 2002, 67: 1379–85.PubMedCrossRefGoogle Scholar
  18. 18.
    O’Neill K, Chen S, Brinton RD. Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer’s disease. Exp Neurol 2004, 185: 63–80.PubMedCrossRefGoogle Scholar
  19. 19.
    O’Neill K, Chen S, Brinton RD. Impact of the selective estrogen receptor modulator, tamoxifen, on neuronal outgrowth and survival following toxic insults associated with aging and Alzheimer’s disease. Exp Neurol 2004, 188: 268–78.PubMedCrossRefGoogle Scholar
  20. 20.
    Yaffe K, Krueger K, Sarkar S et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 2001, 344: 1207–13.PubMedCrossRefGoogle Scholar
  21. 21.
    Greeve I, Hermans-Borgmeyer I, Brellinger C, et al. The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer’s disease-associated neurodegeneration and oxidative stress. J Neurosci 2001, 20: 7345–52.Google Scholar
  22. 22.
    Iivonen S, Hiltunen M, Alafuzoff I, et al. Seladin-1 transcription is linked to neuronal degeneration in Alzheimer’s disease. Neuroscience 2002, 113: 301–10.PubMedCrossRefGoogle Scholar
  23. 23.
    Sarkar D, Imai T, Kambe F, et al. The human homolog of Diminuto/Dwarf1 gene (hDiminuto): a novel ACTH-responsive gene overexpressed in benign cortisol-producing adrenocortical adenomas. J Clin Endocrinol Metab 2001, 86: 5130–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Luciani P, Ferruzzi P, Arnaldi G et al. Expression of the novel ACTH-responsive gene seladin-1/DHCR24 in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. J Clin Endocrinol Metab 2004, 89: 1332–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Wu C, Miloslavskaya I, Demontis S, Maestro R, Galaktionov K. Regulation of cellular response to oncogenic and oxidative stress by Seladin-1. Nature 2004, 432: 640–5.PubMedCrossRefGoogle Scholar
  26. 26.
    FitzPatrick DR, Keeling JW, Evans MJ et al. Clinical phenotype of desmosterolosis. Am J Med Genet 1998, 75: 145–52.PubMedCrossRefGoogle Scholar
  27. 27.
    Waterham HR, Koster J, Romeijn GJ et al. Mutations in the 3beta-hydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. Am J Hum Genet 2001, 69: 685–94.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Herman GE. Disorders of cholesterol biosynthesis: prototypic metabolic malformation syndromes. Hum Mol Genet 2003, 12 Spec No 1: R75–88.PubMedCrossRefGoogle Scholar
  29. 29.
    Yanagisawa K. Cholesterol and pathological processes in Alzheimer’s disease. J Neurosci Res 2002, 70: 361–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Puglielli L, Tanzi RE, Kovacs DM. Alzheimer’s disease: the cholesterol connection. Nat Neurosci 2003, 6: 345–51.PubMedCrossRefGoogle Scholar
  31. 31.
    Reiss AB, Siller KA, Rahman MM, Chan ES, Ghiso J, de Leon MJ. Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer’s disease. Neurobiol Aging 2004, 25: 977–89.PubMedCrossRefGoogle Scholar
  32. 32.
    Arispe N, Doh M. Plasma membrane cholesterol controls the cytotoxicity of Alzheimer’s disease AbetaP (1–40) and (1–42) peptides. FASEB J 2002, 16: 1526–36.PubMedCrossRefGoogle Scholar
  33. 33.
    Wechsler A, Brafman A, Shafir M et al. Generation of viable cholesterol-free mice. Science 2003, 302: 2087.PubMedCrossRefGoogle Scholar
  34. 34.
    Rothblat GH, Burns CH, Conner RL, Landrey JR. Desmosterol as the major sterol in L-cell mouse fibroblasts grown in sterol-free culture medium. Science 1970, 169: 880–2.PubMedCrossRefGoogle Scholar
  35. 35.
    Schumacher K, Chory J. Brassinosteroid signal transduction: still casting the actors. Curr Opin Plant Biol 2000, 3: 79–84.PubMedCrossRefGoogle Scholar
  36. 36.
    Clouse SD, Sasse JM. BRASSINOSTEROIDS: Essential Regulators of Plant Growth and Development. Annu Rev Plant Physiol Plant Mol Biol 1998, 49: 427–51.PubMedCrossRefGoogle Scholar
  37. 37.
    Klahre U, Noguchi T, Fujioka S et al. The Arabidopsis DIMINUTO/DWARF1 gene encodes a protein involved in steroid synthesis. Plant Cell 1998, 10: 1677–90.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Clouse SD. Arabidopsis mutants reveal multiple roles for sterols in plant development. Plant Cell 2002, 14: 1995–2000.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Choe S, Dilkes BP, Gregory BD et al. The Arabidopsis dwarf1 mutant is defective in the conversion of 24-methylenecholesterol to campesterol in brassinosteroid biosynthesis. Plant Physiol 1999, 119: 897–907.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Suzuki M, Kamide Y, Nagata N et al. Loss of function of 3-hydroxy-3-methylglutaryl coenzyme A reductase 1 (HMG1) in Arabidopsis leads to dwarfing, early senescence and male sterility, and reduced sterol levels. Plant J 2004, 37: 750–61.PubMedCrossRefGoogle Scholar
  41. 41.
    Lutjohann D, Brzezinka A, Barth E et al. Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. J Lipid Res 2002, 43: 1078–85.PubMedCrossRefGoogle Scholar
  42. 42.
    Vannelli GB, Ensoli F, Zonefrati R et al. Neuroblast long-term cell cultures from human fetal olfactory epithelium respond to odors. J Neurosci 1995, 15: 4282–94.Google Scholar
  43. 43.
    Barni T, Maggi M, Fantoni G et al. Sex steroids and odorants modulate gonadotropin-releasing hormone secretion in primary cultures of human olfactory cells. J Clin Endocrinol Metab 1999, 84: 4266–73.PubMedGoogle Scholar
  44. 44.
    Benvenuti S, Luciani P, Vannelli GB et al. Estrogen and SERMs exert neuroprotective effects and stimulate the expression of seladin-1, a recently discovered anti-apoptotic gene, in human neuroblast long-term cell cultures. J Clin Endocrinol Metab 2005, 90: 1775–82.PubMedCrossRefGoogle Scholar
  45. 45.
    Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA, Katzenellenbogen BS. Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol Cell Endocrinol 2003, 206: 13–22.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2005

Authors and Affiliations

  1. 1.Department of Clinical Physiopathology, Endocrine Unit, Center for Research, Transfer and High Education on Chronic, Inflammatory, Degenerative and Neoplastic Disorders for the Development of Novel TherapiesUniversity of FlorenceFlorenceItaly

Personalised recommendations